StudyFinder

HM2023-07: Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone (DPd), in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 1 Prior Line of Therapy

Recruiting

Talquetamab is an experimental medication being studied to see if it may be beneficial in the treatment of multiple myeloma.

I'm interested

Male or Female
18 years and over
This study is NOT accepting healthy volunteers
Inclusion Criteria:

• diagnosed with multiple myeloma that has not responded to treatment or has reoccurred after at least one treatment
• able to care for self with some assistance
Exclusion Criteria:

• active cancer in central nervous system or clinical symptoms
• maximum amount of steriods taken in the past two weeks (study staff will review)
• disease hasn't responded to this type of drug (anti-CD38 monoclonal antibody)

Drug: Daratumumab, Drug: Dexamethasone, Drug: Pomalidomide, Drug: Talquetamab

Cancer

Multiple Myeloma

Daniel O'Leary - dholeary@umn.edu
Daniel O'Leary
PHASE3
STUDY00018679
See this study on ClinicalTrials.gov

Back